Amyris Named Gold 2016 Edison Award Winner -- One of Highest Accolades for Innovation in Business
April 28 2016 - 11:46AM
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is
pleased to announce it has been named a Gold Edison Award winner
for its collaborative development work on production of artemisinin
for life-saving artemisinin combination therapies (ACTs), the World
Health Organization’s recommended first-line treatment for malaria.
The Edison Awards, named after inventor Thomas Edison, are among
the most prestigious accolades a company can receive and honor new
product and service development, marketing, human-centered design
and innovation that are considered “game-changing.”
“Amyris is honored to be among the globally recognized business
leaders to have received this prestigious award, which highlights
our collaborative excellence in harnessing our advanced technology
platform and innovation to help solve global problems,” said John
Melo, Amyris President & CEO. “This showcases the hard work of
our world-class scientists and the success in working with our
partners.”
Continued Melo, “We are applying our platform beyond the
development of artemisinin, and expect our platform to support and
accelerate drug discovery for companies in the biopharma space
where we are in active discussions with several potential
partners.”
Advantaged Platform for Pharmaceutical Development
Amyris's advanced synthetic biology platform combines high-speed
genomic engineering with high-performance screening and production
scale-up, which provides a powerful alternative to support
development and production of pharmaceutical precursors or
ingredients such as artemisinic acid. By encoding microbes to
efficiently produce molecules, Amyris has shown that its technology
can help partners achieve cost-effective manufacturing of pure,
high-quality ingredients very quickly. Amyris’s ability to
manufacture natural and natural-like products also means that
previously scarce or unavailable materials can be generated for all
phases of pharmaceutical development – from screening for target
functionality, through clinical trials, all the way to full-scale
production.
Edison Award nominees are judged by more than 3,000 senior
business executives and academics from across the nation whose
votes acknowledge the Finalists’ success in meeting the award’s
stringent criteria of quality. The Edison Awards is a program
conducted by Edison Universe, a 501(c)(3) charitable organization
dedicated to fostering future innovators. For more information
about the Edison Awards, Edison Universe and a list of past
winners, visit www.edisonawards.com.
About Amyris
Amyris is the integrated renewable products company that is
enabling the world’s leading brands to achieve sustainable growth.
Amyris applies its innovative bioscience solutions to convert plant
sugars into hydrocarbon molecules, specialty ingredients and
consumer products. The company is delivering its No Compromise®
products in focused markets, including specialty and performance
chemicals, fragrance ingredients, and cosmetic emollients. More
information about the company is available at www.amyris.com.
Forward-Looking StatementsThis release contains
forward-looking statements, and any statements other than
statements of historical facts could be deemed to be
forward-looking statements. These forward-looking statements
include, among other things, statements regarding future events
(such as use of the Amyris technology platform beyond production of
artemisinin to support and accelerate drug discovery for companies
in the biopharma space, ability of Amyris technology to generate
material for all phases of pharmaceutical development, prospects
for collaborations with pharmaceutical companies, and other
potential benefits Amyris can provide to prospective pharmaceutical
collaboration partners), that involve risks and uncertainties.
These statements are based on management’s current expectations and
actual results and future events may differ materially due to risks
and uncertainties, including the company's liquidity and
ability to fund operating and capital expenses, Amyris's reliance
on third parties to achieve its goals, timing and execution risks
associated with development and manufacturing, potential delays or
failures in development, production and commercialization of
products, and other risks detailed in the “Risk Factors” section of
Amyris’s annual report on Form 10-K filed on March 30, 2016. Amyris
disclaims any obligation to update information contained in these
forward-looking statements whether as a result of new information,
future events, or otherwise.
Amyris and the Amyris logo are registered trademarks of Amyris,
Inc. All other trademarks are the property of their respective
owners.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Apr 2023 to Apr 2024